Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series

Blood Cancer Journal 2026 Open access

Read full text
Authors: Sandra Susanibar-Adaniya, Benjamin Avi Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J Frigualt, Andrew J Yee, Binod Dhakal, Noffar Bar
DOI: 10.1038/s41408-026-01473-3
Cited by: 1
References: 11

Abstract

Chimeric antigen receptor T-cell therapy (CART) targeting B cell maturation antigen (BCMA) is an effective treatment for relapsed multiple myeloma (MM). However, immune-mediated toxicities resembling autoimmune diseases or graft-versus-host disease (GVHD) are increasingly recognized but remain poorly understood. We describe the largest multicenter series to date of immune effector cell-associated enterocolitis (IEC-EC) after BCMA-CART, characterizing its clinical course, pathology, and outcomes.

Fields of Study & Subjects

CAR-T cell therapy research Celiac Disease Research and Management T-cell and B-cell Immunology

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
28 April 2026
Language
EN